Cases & Deals

Share

Franklin Templeton invests in Edge Therapeutics

April 2015

Client(s) Franklin Templeton

Jones Day advised Franklin Templeton in connection with its purchase of Series C-2 Convertible Preferred Stock in a private placement by Edge Therapeutics, Inc., a clinical-stage biotechnology company that discovers, develops, and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.